{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:09:27Z","timestamp":1790986167493,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10741-019-09869-z","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T11:03:42Z","timestamp":1574161422000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Hyperuricemia: a novel old disorder\u2014relationship and potential mechanisms in heart failure"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Landolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"9869_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","volume":"484","author":"G Ndrepepa","year":"2018","unstructured":"Ndrepepa G (2018) Uric acid and cardiovascular disease. Clin Chim Acta 484:150\u2013163. https:\/\/doi.org\/10.1016\/j.cca.2018.05.046","journal-title":"Clin Chim Acta"},{"key":"9869_CR2","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.1073\/pnas.86.23.9412","volume":"86","author":"XW Wu","year":"1989","unstructured":"Wu XW, Lee CC, Muzny DM, Caskey CT (1989) Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci 86:9412\u20139416. https:\/\/doi.org\/10.1073\/pnas.86.23.9412","journal-title":"Proc Natl Acad Sci"},{"key":"9869_CR3","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"9869_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF00163854","volume":"34","author":"X Wu","year":"1992","unstructured":"Wu X, Muzny DM, Chi Lee C, Thomas Caskey C (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34:78\u201384. https:\/\/doi.org\/10.1007\/BF00163854","journal-title":"J Mol Evol"},{"key":"9869_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","volume":"131","author":"BF Culleton","year":"1999","unstructured":"Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7. https:\/\/doi.org\/10.7326\/0003-4819-131-1-199907060-00003","journal-title":"Ann Intern Med"},{"key":"9869_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","volume":"33","author":"C Borghi","year":"2015","unstructured":"Borghi C, Rosei EA, Bardin T et al (2015) Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 33:1729\u20131741. https:\/\/doi.org\/10.1097\/HJH.0000000000000701","journal-title":"J Hypertens"},{"key":"9869_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchromb.2008.11.029","volume":"877","author":"KM Kim","year":"2009","unstructured":"Kim KM, Henderson GN, Frye RF et al (2009) Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography\u2013mass spectrometry. J Chromatogr B 877:65\u201370. https:\/\/doi.org\/10.1016\/j.jchromb.2008.11.029","journal-title":"J Chromatogr B"},{"key":"9869_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","volume":"19","author":"IA Bobulescu","year":"2012","unstructured":"Bobulescu IA, Moe OW (2012) Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19:358\u2013371. https:\/\/doi.org\/10.1053\/j.ackd.2012.07.009","journal-title":"Adv Chronic Kidney Dis"},{"key":"9869_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T (2010) Gout. Lancet 375:318\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(09)60883-7","journal-title":"Lancet"},{"key":"9869_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/HYPERTENSIONAHA.115.06531","volume":"67","author":"C Borghi","year":"2016","unstructured":"Borghi C, Desideri G (2016) Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension 67:496\u2013498. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06531","journal-title":"Hypertension"},{"key":"9869_CR11","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1161\/01.CIR.0000041431.57222.AF","volume":"106","author":"U Landmesser","year":"2002","unstructured":"Landmesser U, Spiekermann S, Dikalov S et al (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106:3073\u20133078. https:\/\/doi.org\/10.1161\/01.CIR.0000041431.57222.AF","journal-title":"Circulation"},{"key":"9869_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87\u2013114. https:\/\/doi.org\/10.1124\/pr.58.1.6","journal-title":"Pharmacol Rev"},{"key":"9869_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143:499. https:\/\/doi.org\/10.7326\/0003-4819-143-7-200510040-00009","journal-title":"Ann Intern Med"},{"key":"9869_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12012-002-0002-7","volume":"2","author":"D Cooper","year":"2002","unstructured":"Cooper D, Stokes KY, Tailor A, Granger DN (2002) Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol 2:165\u2013180. https:\/\/doi.org\/10.1007\/s12012-002-0002-7","journal-title":"Cardiovasc Toxicol"},{"key":"9869_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijcard.2015.08.086","volume":"213","author":"S Biscaglia","year":"2016","unstructured":"Biscaglia S, Ceconi C, Malag\u00f9 M et al (2016) Uric acid and coronary artery disease: an elusive link deserving further attention. Int J Cardiol 213:28\u201332. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.086","journal-title":"Int J Cardiol"},{"key":"9869_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/15257770802257952","volume":"27","author":"C Gersch","year":"2008","unstructured":"Gersch C, Palii SP, Kim KM et al (2008) Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 27:967\u2013978. https:\/\/doi.org\/10.1080\/15257770802257952","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"9869_CR17","doi-asserted-by":"publisher","first-page":"C1183","DOI":"10.1152\/ajpcell.00075.2008","volume":"295","author":"S Zharikov","year":"2008","unstructured":"Zharikov S, Krotova K, Hu H et al (2008) Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Phys Cell Phys 295:C1183\u2013C1190. https:\/\/doi.org\/10.1152\/ajpcell.00075.2008","journal-title":"Am J Phys Cell Phys"},{"key":"9869_CR18","doi-asserted-by":"publisher","first-page":"e0145093","DOI":"10.1371\/journal.pone.0145093","volume":"10","author":"C Dhanasekar","year":"2015","unstructured":"Dhanasekar C, Kalaiselvan S, Rasool M (2015) Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-\u03baB activation. PLOS ONE 10:e0145093. https:\/\/doi.org\/10.1371\/journal.pone.0145093","journal-title":"PLOS ONE"},{"key":"9869_CR19","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/art.21238","volume":"52","author":"R Liu-Bryan","year":"2005","unstructured":"Liu-Bryan R, Scott P, Sydlaske A et al (2005) Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 52:2936\u20132946. https:\/\/doi.org\/10.1002\/art.21238","journal-title":"Arthritis Rheum"},{"issue":"12","key":"9869_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, for CANTOS Trial Group et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131","journal-title":"N Engl J Med"},{"key":"9869_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119:159\u2013176. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308030","journal-title":"Circ Res"},{"key":"9869_CR22","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/eurheartj\/ehv653","volume":"37","author":"A Janoudi","year":"2016","unstructured":"Janoudi A, Shamoun FE, Kalavakunta JK, Abela GS (2016) Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. Eur Heart J 37:1959\u20131967. https:\/\/doi.org\/10.1093\/eurheartj\/ehv653","journal-title":"Eur Heart J"},{"key":"9869_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/HJH.0b013e328337a9e3","volume":"28","author":"G Mancia","year":"2010","unstructured":"Mancia G, Bombelli M, Facchetti R et al (2010) Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. J Hypertens 28:999\u20131006. https:\/\/doi.org\/10.1097\/HJH.0b013e328337a9e3","journal-title":"J Hypertens"},{"key":"9869_CR24","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640\u20131645. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"key":"9869_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2337\/diacare.28.7.1769","volume":"28","author":"ES Ford","year":"2005","unstructured":"Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769\u20131778","journal-title":"Diabetes Care"},{"key":"9869_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/HYPERTENSIONAHA.117.09508","volume":"70","author":"T Han","year":"2017","unstructured":"Han T, Lan L, Qu R et al (2017) Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertension 70:703\u2013711. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09508","journal-title":"Hypertension"},{"key":"9869_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/acr.20344","volume":"63","author":"PC Grayson","year":"2011","unstructured":"Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis: risk of incident hypertension associated with hyperuricemia. Arthritis Care Res 63:102\u2013110. https:\/\/doi.org\/10.1002\/acr.20344","journal-title":"Arthritis Care Res"},{"key":"9869_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","volume":"41","author":"RJ Johnson","year":"2003","unstructured":"Johnson RJ, Kang D-H, Feig D et al (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183\u20131190. https:\/\/doi.org\/10.1161\/01.HYP.0000069700.62727.C5","journal-title":"Hypertension"},{"key":"9869_CR29","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0b013e32830e4945","volume":"26","author":"P Men\u00e8","year":"2008","unstructured":"Men\u00e8 P, Punzo G (2008) Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 26:2085\u20132092. https:\/\/doi.org\/10.1097\/HJH.0b013e32830e4945","journal-title":"J Hypertens"},{"key":"9869_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","volume":"56","author":"G Bellomo","year":"2010","unstructured":"Bellomo G, Venanzi S, Verdura C et al (2010) Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 56:264\u2013272. https:\/\/doi.org\/10.1053\/j.ajkd.2010.01.019","journal-title":"Am J Kidney Dis"},{"key":"9869_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"C Hsu","year":"2009","unstructured":"Hsu C, Iribarren C, McCulloch CE et al (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169:342. https:\/\/doi.org\/10.1001\/archinternmed.2008.605","journal-title":"Arch Intern Med"},{"key":"9869_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/rheumatology\/kes223","volume":"52","author":"C-F Kuo","year":"2013","unstructured":"Kuo C-F, See L-C, Yu K-H et al (2013) Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology 52:127\u2013134. https:\/\/doi.org\/10.1093\/rheumatology\/kes223","journal-title":"Rheumatology"},{"key":"9869_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1047-2797(99)00037-X","volume":"10","author":"JT Moriarity","year":"2000","unstructured":"Moriarity JT, Folsom AR, Iribarren C et al (2000) Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 10:136\u2013143","journal-title":"Ann Epidemiol"},{"key":"9869_CR34","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/ar3322","volume":"13","author":"E Krishnan","year":"2011","unstructured":"Krishnan E, Pandya BJ, Chung L, Dabbous O (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study. Arthritis Res Ther 13:R66. https:\/\/doi.org\/10.1186\/ar3322","journal-title":"Arthritis Res Ther"},{"key":"9869_CR35","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","volume":"37","author":"MJ Bos","year":"2006","unstructured":"Bos MJ, Koudstaal PJ, Hofman A et al (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 37:1503\u20131507. https:\/\/doi.org\/10.1161\/01.STR.0000221716.55088.d4","journal-title":"Stroke"},{"key":"9869_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ijcard.2011.06.055","volume":"154","author":"S-Y Chuang","year":"2012","unstructured":"Chuang S-Y, Chen J-H, Yeh W-T et al (2012) Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol 154:316\u2013321. https:\/\/doi.org\/10.1016\/j.ijcard.2011.06.055","journal-title":"Int J Cardiol"},{"key":"9869_CR37","doi-asserted-by":"publisher","first-page":"e106130","DOI":"10.1371\/journal.pone.0106130","volume":"9","author":"J Zhang","year":"2014","unstructured":"Zhang J, He L, Cao S et al (2014) Association of serum uric acid and coronary artery disease in premenopausal women. PLoS One 9:e106130. https:\/\/doi.org\/10.1371\/journal.pone.0106130","journal-title":"PLoS One"},{"key":"9869_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijcard.2008.06.024","volume":"138","author":"C Lazzeri","year":"2010","unstructured":"Lazzeri C, Valente S, Chiostri M et al (2010) Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers. Int J Cardiol 138:206\u2013209. https:\/\/doi.org\/10.1016\/j.ijcard.2008.06.024","journal-title":"Int J Cardiol"},{"key":"9869_CR39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.amjcard.2011.12.018","volume":"109","author":"G Ndrepepa","year":"2012","unstructured":"Ndrepepa G, Braun S, Haase H-U et al (2012) Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol 109:1260\u20131265. https:\/\/doi.org\/10.1016\/j.amjcard.2011.12.018","journal-title":"Am J Cardiol"},{"key":"9869_CR40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijcard.2018.03.077","volume":"261","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Kuwabara M, Johnson R et al (2018) LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the Brisighella Heart Study cohort. Int J Cardiol 261:204\u2013208. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.077","journal-title":"Int J Cardiol"},{"key":"9869_CR41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1055\/s-2007-991158","volume":"39","author":"R Catar","year":"2007","unstructured":"Catar R, M\u00fcller G, Heidler J et al (2007) Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res 39:801\u2013805. https:\/\/doi.org\/10.1055\/s-2007-991158","journal-title":"Horm Metab Res"},{"key":"9869_CR42","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.amjcard.2015.07.059","volume":"116","author":"Y Saito","year":"2015","unstructured":"Saito Y, Nakayama T, Sugimoto K et al (2015) Relation of lipid content of coronary plaque to level of serum uric acid. Am J Cardiol 116:1346\u20131350. https:\/\/doi.org\/10.1016\/j.amjcard.2015.07.059","journal-title":"Am J Cardiol"},{"key":"9869_CR43","doi-asserted-by":"publisher","first-page":"932","DOI":"10.5551\/jat.33951","volume":"23","author":"K Ando","year":"2016","unstructured":"Ando K, Takahashi H, Watanabe T et al (2016) Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease. J Atheroscler Thromb 23:932\u2013939. https:\/\/doi.org\/10.5551\/jat.33951","journal-title":"J Atheroscler Thromb"},{"key":"9869_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","volume":"151","author":"S Hamaguchi","year":"2011","unstructured":"Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M et al (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151:143\u2013147. https:\/\/doi.org\/10.1016\/j.ijcard.2010.05.002","journal-title":"Int J Cardiol"},{"key":"9869_CR45","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","volume":"107","author":"SD Anker","year":"2003","unstructured":"Anker SD, Doehner W, Rauchhaus M et al (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107:1991\u20131997. https:\/\/doi.org\/10.1161\/01.CIR.0000065637.10517.A0","journal-title":"Circulation"},{"key":"9869_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10741-012-9322-2","volume":"18","author":"M Kaufman","year":"2013","unstructured":"Kaufman M, Guglin M (2013) Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev 18:177\u2013186. https:\/\/doi.org\/10.1007\/s10741-012-9322-2","journal-title":"Heart Fail Rev"},{"key":"9869_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1751-7133.2008.00005.x","volume":"14","author":"C Chrysohoou","year":"2008","unstructured":"Chrysohoou C, Pitsavos C, Barbetseas J et al (2008) Serum uric acid levels correlate with left atrial function and systolic right ventricular function in patients with newly diagnosed heart failure: the Hellenic Heart Failure Study: the Hellenic Heart Failure Study. Congest Heart Fail 14:229\u2013233. https:\/\/doi.org\/10.1111\/j.1751-7133.2008.00005.x","journal-title":"Congest Heart Fail"},{"key":"9869_CR48","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/eurheartj\/ehq473","volume":"32","author":"GS Filippatos","year":"2011","unstructured":"Filippatos GS, Ahmed MI, Gladden JD et al (2011) Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 32:712\u2013720. https:\/\/doi.org\/10.1093\/eurheartj\/ehq473","journal-title":"Eur Heart J"},{"key":"9869_CR49","doi-asserted-by":"publisher","first-page":"H1123","DOI":"10.1152\/ajpheart.00533.2015","volume":"309","author":"T Shimizu","year":"2015","unstructured":"Shimizu T, Yoshihisa A, Kanno Y et al (2015) Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction. Am J Phys Heart Circ Phys 309:H1123\u2013H1129. https:\/\/doi.org\/10.1152\/ajpheart.00533.2015","journal-title":"Am J Phys Heart Circ Phys"},{"key":"9869_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","volume":"16","author":"H Huang","year":"2014","unstructured":"Huang H, Huang B, Li Y et al (2014) Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 16:15\u201324. https:\/\/doi.org\/10.1093\/eurjhf\/hft132","journal-title":"Eur J Heart Fail"},{"key":"9869_CR51","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/eci.12273","volume":"44","author":"C Borghi","year":"2014","unstructured":"Borghi C, Cosentino ER, Rinaldi ER, Cicero AFG (2014) Uricaemia and ejection fraction in elderly heart failure outpatients. Eur J Clin Investig 44:573\u2013577. https:\/\/doi.org\/10.1111\/eci.12273","journal-title":"Eur J Clin Investig"},{"key":"9869_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1751-7133.2010.00205.x","volume":"17","author":"A Amin","year":"2011","unstructured":"Amin A, Vakilian F, Maleki M (2011) Serum uric acid levels correlate with filling pressures in systolic heart failure: filling pressures in systolic heart failure. Congest Heart Fail 17:79\u201383. https:\/\/doi.org\/10.1111\/j.1751-7133.2010.00205.x","journal-title":"Congest Heart Fail"},{"key":"9869_CR53","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1067\/mhj.2002.122122","volume":"143","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Rossi A et al (2002) Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143:1107\u20131111","journal-title":"Am Heart J"},{"key":"9869_CR54","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.amjcard.2016.02.039","volume":"117","author":"A Palazzuoli","year":"2016","unstructured":"Palazzuoli A, Ruocco G, Pellegrini M et al (2016) Prognostic significance of hyperuricemia in patients with acute heart failure. Am J Cardiol 117:1616\u20131621. https:\/\/doi.org\/10.1016\/j.amjcard.2016.02.039","journal-title":"Am J Cardiol"},{"key":"9869_CR55","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.amjcard.2014.09.008","volume":"114","author":"M Vaduganathan","year":"2014","unstructured":"Vaduganathan M, Greene SJ, Ambrosy AP et al (2014) Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial). Am J Cardiol 114:1713\u20131721. https:\/\/doi.org\/10.1016\/j.amjcard.2014.09.008","journal-title":"Am J Cardiol"},{"key":"9869_CR56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejheart.2006.09.001","volume":"9","author":"DA Pascual-Figal","year":"2007","unstructured":"Pascual-Figal DA, Hurtado-Mart\u00ednez JA, Redondo B et al (2007) Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 9:518\u2013524. https:\/\/doi.org\/10.1016\/j.ejheart.2006.09.001","journal-title":"Eur J Heart Fail"},{"key":"9869_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2016.11.077","volume":"228","author":"Y Otaki","year":"2017","unstructured":"Otaki Y, Watanabe T, Kinoshita D et al (2017) Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol 228:151\u2013157. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.077","journal-title":"Int J Cardiol"},{"issue":"5","key":"9869_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/rheumatology\/kew293)","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 56(5):679\u2013688. https:\/\/doi.org\/10.1093\/rheumatology\/kew293)","journal-title":"Rheumatology (Oxford)"},{"key":"9869_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.amjmed.2015.11.003","volume":"129","author":"KS Larsen","year":"2016","unstructured":"Larsen KS, Potteg\u00e5rd A, Lindegaard HM, Hallas J (2016) Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med 129:299\u2013306.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2015.11.003","journal-title":"Am J Med"},{"key":"9869_CR60","doi-asserted-by":"publisher","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","volume":"4","author":"TM MacDonald","year":"2014","unstructured":"MacDonald TM, Ford I, Nuki G et al (2014) Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 4:e005354. https:\/\/doi.org\/10.1136\/bmjopen-2014-005354","journal-title":"BMJ Open"},{"key":"9869_CR61","doi-asserted-by":"publisher","first-page":"e013774","DOI":"10.1136\/bmjopen-2016-013774","volume":"6","author":"IS Mackenzie","year":"2016","unstructured":"Mackenzie IS, Ford I, Walker A et al (2016) Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open 6:e013774. https:\/\/doi.org\/10.1136\/bmjopen-2016-013774","journal-title":"BMJ Open"},{"key":"9869_CR62","doi-asserted-by":"publisher","first-page":"653.e7","DOI":"10.1016\/j.amjmed.2015.01.013","volume":"128","author":"SC Kim","year":"2015","unstructured":"Kim SC, Schneeweiss S, Choudhry N et al (2015) Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med 128:653.e7\u2013653.e16. https:\/\/doi.org\/10.1016\/j.amjmed.2015.01.013","journal-title":"Am J Med"},{"key":"9869_CR63","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/hrt.2004.040477","volume":"91","author":"AD Gavin","year":"2005","unstructured":"Gavin AD (2005) Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91:749\u2013753. https:\/\/doi.org\/10.1136\/hrt.2004.040477","journal-title":"Heart"},{"key":"9869_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/bmj.330.7492.625","volume":"330","author":"JA Doust","year":"2005","unstructured":"Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330:625. https:\/\/doi.org\/10.1136\/bmj.330.7492.625","journal-title":"BMJ"},{"key":"9869_CR65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cardfail.2006.05.005","volume":"12","author":"HE Cingolani","year":"2006","unstructured":"Cingolani HE, Plastino JA, Escudero EM et al (2006) The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 12:491\u2013498. https:\/\/doi.org\/10.1016\/j.cardfail.2006.05.005","journal-title":"J Card Fail"},{"key":"9869_CR66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","volume":"3","author":"K Ogino","year":"2010","unstructured":"Ogino K, Kato M, Furuse Y et al (2010) Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 3:73\u201381. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.868604","journal-title":"Circ Heart Fail"},{"key":"9869_CR67","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1161\/hc4501.098928","volume":"104","author":"TP Cappola","year":"2001","unstructured":"Cappola TP, Kass DA, Nelson GS et al (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104:2407\u20132411","journal-title":"Circulation"},{"key":"9869_CR68","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450\u20132461. https:\/\/doi.org\/10.1056\/NEJMoa050373","journal-title":"N Engl J Med"},{"key":"9869_CR69","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/01.CIR.0000144303.24894.1C","volume":"110","author":"N Engberding","year":"2004","unstructured":"Engberding N, Spiekermann S, Schaefer A et al (2004) Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110:2175\u20132179. https:\/\/doi.org\/10.1161\/01.CIR.0000144303.24894.1C","journal-title":"Circulation"},{"key":"9869_CR70","first-page":"756","volume":"20","author":"J Xiao","year":"2016","unstructured":"Xiao J, Deng S-B, She Q et al (2016) Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. Eur Rev Med Pharmacol Sci 20:756\u2013761","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"9869_CR71","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","volume":"51","author":"JM Hare","year":"2008","unstructured":"Hare JM, Mangal B, Brown J et al (2008) Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol 51:2301\u20132309. https:\/\/doi.org\/10.1016\/j.jacc.2008.01.068","journal-title":"J Am Coll Cardiol"},{"key":"9869_CR72","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz MM, Anstrom KJ, Redfield MM et al (2015) Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 131:1763\u20131771. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014536","journal-title":"Circulation"},{"key":"9869_CR73","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","volume":"69","author":"S Kojima","year":"2017","unstructured":"Kojima S, Matsui K, Ogawa H et al (2017) Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol 69:169\u2013175. https:\/\/doi.org\/10.1016\/j.jjcc.2016.02.015","journal-title":"J Cardiol"},{"key":"9869_CR74","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S et al (2018) Febuxostat therapy for patients with stage 3 ckd and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72:798\u2013810. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.028","journal-title":"Am J Kidney Dis"},{"key":"9869_CR75","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","volume":"138","author":"M Zhang","year":"2018","unstructured":"Zhang M, Solomon DH, Desai RJ et al (2018) Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation 138:1116\u20131126. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033992","journal-title":"Circulation"},{"key":"9869_CR76","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"key":"9869_CR77","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1161\/CIRCULATIONAHA.118.037976","volume":"139","author":"M Kuwabara","year":"2019","unstructured":"Kuwabara M (2019) Letter by Kuwabara regarding article, \u201cAssessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.\u201d. Circulation 139:1348\u20131349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037976","journal-title":"Circulation"},{"key":"9869_CR78","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1536\/ihj.17-560","volume":"59","author":"T Yokota","year":"2018","unstructured":"Yokota T, Fukushima A, Kinugawa S et al (2018) Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF): study design. Int Heart J 59:976\u2013982. https:\/\/doi.org\/10.1536\/ihj.17-560","journal-title":"Int Heart J"},{"key":"9869_CR79","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1021\/acs.jmedchem.6b01818","volume":"60","author":"Y Li","year":"2017","unstructured":"Li Y, Shi Z, Chen L et al (2017) Discovery of a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor (HSK0935) for the treatment of type 2 diabetes. J Med Chem 60:4173\u20134184. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01818","journal-title":"J Med Chem"},{"key":"9869_CR80","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria: uricosuric effect Of SGLT2 inhibitor. Biopharm Drug Dispos 35:391\u2013404. https:\/\/doi.org\/10.1002\/bdd.1909","journal-title":"Biopharm Drug Dispos"},{"key":"9869_CR81","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/dom.12439","volume":"17","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Trujillo A, Vijapurkar U et al (2015) Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab 17:426\u2013429. https:\/\/doi.org\/10.1111\/dom.12439","journal-title":"Diabetes Obes Metab"},{"key":"9869_CR82","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"9869_CR83","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"9869_CR84","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 41:356\u2013363. https:\/\/doi.org\/10.2337\/dc17-1096","journal-title":"Diabetes Care"},{"key":"9869_CR85","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"9869_CR86","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.1056","volume":"20","author":"UM Mogensen","year":"2018","unstructured":"Mogensen UM, K\u00f8ber L, Jhund PS et al (2018) Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF: sacubitril\/valsartan, uric acid, and heart failure. Eur J Heart Fail 20:514\u2013522. https:\/\/doi.org\/10.1002\/ejhf.1056","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"9869_CR87","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"Daniel I. Feig","year":"2008","unstructured":"Feig D, Soletsky B, Johnson R (2008) Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension. JAMA 300 (8):924.","journal-title":"JAMA"},{"issue":"7","key":"9869_CR88","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2337\/db17-0168","volume":"66","author":"Yuliya Lytvyn","year":"2017","unstructured":"Lytvyn Y, Har R, Locke A et al (2017) Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. Diabetes 66 (7):1939-1949.","journal-title":"Diabetes"},{"issue":"12","key":"9869_CR89","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40261-015-0349-8","volume":"35","author":"Shigemasa Tani","year":"2015","unstructured":"Tani S, Nagao K, Hirayama A (2015) Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study. Clin Drug Investig 35 (12):823-831.","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"9869_CR90","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","volume":"65","author":"Marian Goicoechea","year":"2015","unstructured":"Goicoechea M, Garcia de Vinuesa S, Verdalles U et al (2015) Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial. Am J Kidney Dis 65 (4):543-549.","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"9869_CR91","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3899\/jrheum.141037","volume":"42","author":"Hong Meng","year":"2015","unstructured":"Meng H, Liu G, Zhai J et al (2015) Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia \u2014 The PUSH-PATH3 Study. The Journal of Rheumatology 42 (5):866-869.","journal-title":"The Journal of Rheumatology"},{"issue":"9732","key":"9869_CR92","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"Awsan Noman","year":"2010","unstructured":"Noman A, Ang D, Ogston S et al (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. The Lancet 375 (9732):2161-2167.","journal-title":"The Lancet"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09869-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09869-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09869-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T23:54:14Z","timestamp":1605657254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09869-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["9869"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09869-z","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"19 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}